Prodotti competitors / Area Kite 1 dicembre 2023 Autolus's obecabtagene autoleucel (obe-cel) application in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) expected to be submitted to the EMA in first half of 2024
